Inceptionr LLC Purchases New Shares in ADMA Biologics, Inc. (NASDAQ:ADMA)

Inceptionr LLC purchased a new stake in ADMA Biologics, Inc. (NASDAQ:ADMA) during the 4th quarter, HoldingsChannel reports. The firm purchased 26,378 shares of the biotechnology company’s stock, valued at approximately $452,000.

Several other large investors have also added to or reduced their stakes in ADMA. New York State Teachers Retirement System bought a new stake in ADMA Biologics in the third quarter valued at $1,821,000. Janney Montgomery Scott LLC purchased a new position in ADMA Biologics during the third quarter valued at $1,454,000. Robeco Institutional Asset Management B.V. lifted its position in ADMA Biologics by 61.2% during the third quarter. Robeco Institutional Asset Management B.V. now owns 179,084 shares of the biotechnology company’s stock valued at $3,580,000 after buying an additional 68,000 shares during the period. Amalgamated Bank lifted its position in ADMA Biologics by 803.0% during the third quarter. Amalgamated Bank now owns 68,169 shares of the biotechnology company’s stock valued at $1,363,000 after buying an additional 60,620 shares during the period. Finally, Principal Financial Group Inc. lifted its position in ADMA Biologics by 785.7% during the third quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company’s stock valued at $23,872,000 after buying an additional 1,059,394 shares during the period. Institutional investors own 75.68% of the company’s stock.

ADMA Biologics Stock Performance

Shares of ADMA Biologics stock opened at $17.02 on Friday. The business has a fifty day simple moving average of $16.66 and a two-hundred day simple moving average of $17.96. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $4.02 billion, a P/E ratio of 60.79 and a beta of 0.60. ADMA Biologics, Inc. has a 12 month low of $5.88 and a 12 month high of $23.64.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reissued an “overweight” rating and set a $25.00 price objective on shares of ADMA Biologics in a research report on Tuesday, March 4th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.